Advertisement BTG glucarpidase BLA gets FDA acceptance for review - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BTG glucarpidase BLA gets FDA acceptance for review

UK based BTG has received the US Food and Drug Administration (FDA) acceptance for reviewing biologics license application (BLA) of glucarpidase.

Glucarpidase is an investigational product which is indicated for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function.

Additionally, the agency has granted priority review status for glucarpidase BLA.